Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13201442 | 0.85 | TTR (0.70) | TTRFFAR4FFAR1LTA4H | |
| SCHEMBL9889484 | 0.85 | AR (0.58) | TTRALDH1A1GAAL3MBTL1AR | |
| SCHEMBL14667751 | 0.85 | TTR (0.49) | TTRALDH1A1GAAL3MBTL1AR | |
| SCHEMBL30979256 | 0.82 | ALDH1A1 (0.53) | ALDH1A1GAAL3MBTL1ARACHE | |
| SCHEMBL1747441 | 0.82 | ALDH1A1 (0.53) | ALDH1A1GAAL3MBTL1ARACHE | |
| SCHEMBL9889486 | 0.81 | AR (0.48) | TTRALDH1A1GAAL3MBTL1AR | |
| SCHEMBL9889481 | 0.81 | AR (0.56) | TTRALDH1A1GAAL3MBTL1AR | |
| SCHEMBL876331 | 0.81 | EPAS1 (0.48) | TTRALDH1A1L3MBTL1ARFFAR4 | |
| SCHEMBL12195197 | 0.81 | ALDH1A1 (0.58) | ALDH1A1GAAL3MBTL1ARACHE | |
| SCHEMBL10603411 | 0.81 | TTR (0.47) | TTRCARM1PRMT6FFAR4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140378487-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LTD (GB) | 2014-12-25 | — | — | US | disclosed |
| US-8871928-B2 | Tricyclic compounds, preparation methods, and their uses | GLAXO GROUP LIMITED (GB) | 2014-10-28 | — | — | US | disclosed |
| US-20130178488-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2013-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378487-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | LIPG, PCSK9, ENPP2 | TTR 913/4885ALDH1A1 3675/4885GAA 616/4885 |
| US-20130178488-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | LIPG, PCSK9, ENPP2 | TTR 913/4885ALDH1A1 3675/4885GAA 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.